Teva to Host R&D Day on Wednesday, November 11 in New York City

TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva's ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.

GlobeNewsWire • Oct 12, 2026

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

Zacks Investment Research • Oct 12, 2026

Teva wins FDA approval for monthly schizophrenia injection Weltruza

Teva said on Friday it ​had received approval ‌from the US Food and Drug ​Administration for ​its Weltruza drug for ⁠extended-release injectable suspension ​as the first ​and only once-monthly subcutaneous injectable olanzapine for ​adults with schizophrenia.

Reuters • Oct 9, 2026

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease.

Investors Business Daily • Oct 9, 2026

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Teva Pharmaceutical Industries NYSE: TEVA said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for schizophrenia.

MarketBeat • Oct 9, 2026

FDA Approves Teva's New Once-Monthly Schizophrenia Injection

The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to market Weltruza, a once-monthly subcutaneous injectable for adult patients with schizophrenia.

Benzinga • Oct 9, 2026

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Seeking Alpha • Oct 9, 2026

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring required The approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and social functioning, with a systemic safety profile consistent with oral olanzapine 1 As Teva drives forward its Pivot to Growth strategy, the company continues to deliver on its commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchise Teva will hold an investor call and live webcast on Friday, October 9, 2026, 8:00 a.m. ET PARSIPPANY, N.J.

GlobeNewsWire • Oct 9, 2026

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data include a post hoc analysis of safety and efficacy during the initial 8 weeks of treatment with ecopipam, long-term efficacy and safety from an interim analysis of an ongoing open-label extension (OLE) study, post hoc subgroup analyses and preclinical receptor selectivity findings.

GlobeNewsWire • Oct 2, 2026

Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The review evaluates current treatment limitations and details how selectively targeting D1 receptors in the brain's direct motor pathway may offer a differentiated, non-antipsychotic approach for managing tics in pediatric patients.1

GlobeNewsWire • Oct 2, 2026